Home > Insider Trading > Filing (0001415889-24-019907)

Filing Details

Accession Number:: 0001415889-24-019907
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-22 20:25:40
Reporting Period:: 2024-07-22

Accepted Time:: 2024-07-22 20:25:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817241	Artiva Biotherapeutics Inc.	ARTV	Biological Products, (No Disgnostic Substances) (2836)	863614316

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1931382	Gc Corp.	107 Ihyeon-Ro,30Beon-Gil Gilheung-Gu, Yongin-Si Gyeonggi-Do M5 16924		No	No	No	No
1931891	Gc Cell Corp	107 Ihyeon-Ro, 30Beon-Gi Giheung-Gu, Yongin-Si Gyeonggi-Do M5 16924		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-22	667,185	$0.00	1,016,022	No	4	C	Direct
Common Stock	Acquisiton	2024-07-22	330,095	$0.00	1,346,117	No	4	C	Direct
Common Stock	Acquisiton	2024-07-22	294,117	$10.20	1,640,234	No	4	J	Direct
Common Stock	Acquisiton	2024-07-22	1,666,666	$12.00	3,306,900	No	4	P	Direct
Common Stock	Acquisiton	2024-07-22	292,791	$0.00	525,349	No	4	C	Indirect	By GC Cell Corporation
Common Stock	Acquisiton	2024-07-22	62,181	$0.00	587,530	No	4	C	Indirect	By GC Cell Corporation
Common Stock	Acquisiton	2024-07-22	256,316	$10.20	843,846	No	4	J	Indirect	By GC Cell Corporation
Common Stock	Acquisiton	2024-07-22	416,666	$12.00	1,260,512	No	4	P	Indirect	By GC Cell Corporation

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	J	Direct
No	4	P	Direct
No	4	C	Indirect	By GC Cell Corporation
No	4	C	Indirect	By GC Cell Corporation
No	4	J	Indirect	By GC Cell Corporation
No	4	P	Indirect	By GC Cell Corporation

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2024-07-22	667,185	$0.00	667,185	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-07-22	330,095	$0.00	330,095	$0.00
Common Stock	Series A Preferred Stock	Disposition	2024-07-22	292,791	$0.00	292,791	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-07-22	62,181	$0.00	62,181	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock wasconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein.
Represents the conversion of outstanding simple agreement for future equity in the amount of $3,000,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
The shares were purchased in the Issuer's initial public offering.
The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.
Represents the conversion of outstanding simple agreement for future equity in the amount of $2,614,424.28 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.